MSLN and ovarian carcinoma: Given the importance of their interaction for the tumorigenicity of ovarian cancer cells, MUC16 and mesothelin have emerged as putative targets for developing treatments for peritoneal metastasis in epithelial ovarian cancer [14, 15].